Ignite Creation Date:
2024-10-25 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06514560
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-20
Brief Title:
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPTIMILEISH
Brief Summary:
While there are indications that 28 days of miltefosine is not sufficient for treating CL by L aethiopica a better understanding of what happens in terms of parasite clearance and drug dosing is lacking In this study longitudinal measurements of parasite and drug concentrations during treatment are done to monitor parasite kinetics as well as pharmacokinetics This data will be crucial to provide more information on duration and dosing of miltefosine in CL patients globally and in Ethiopia and pediatric patients in particular
Detailed Description:
In this project parasite dynamics and miltefosine pharmacokinetics in the skin and blood during routine durations of miltefosine treatment 4-8 weeks are studied with the aim to provide evidence to optimize miltefosine dosing for treatment of CL By also studying these factors in children who get allometric miltefosine dosing data which can be used to adapt the current allometric dosing scheme specifically to children with CL will be produced Exploratory objectives will look into searching for more objective outcome assessment measures resistance helminth infection and nutritional status as potential factors affecting treatment response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None